2006
Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT
Beer T, Ryan C, Venner P, Petrylak D, Chatta G, Ruether J, Chi K, Arroyo A, Clow F. Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT. Journal Of Clinical Oncology 2006, 24: 4518-4518. DOI: 10.1200/jco.2006.24.18_suppl.4518.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerMetastatic androgen-independent prostate cancerMulti-institutional trialSerum PSAIntermittent chemotherapyChemotherapy holidayTreatment holidayDN-101Large multi-institutional trialsOverall PSA response rateDocetaxel-containing chemotherapyFirst large trialPSA response rateResumption of treatmentPhase III studyMinority of patientsPhase II dataStable PSASame regimenIII studyMedian durationMost patientsSurvival benefitLarge trialsPSA valuesSkeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT
Chan J, Ryan C, Venner P, Petrylak D, Chatta G, Ruether J, Chi K, Young J, Shen C, Beer T. Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT. Journal Of Clinical Oncology 2006, 24: 4614-4614. DOI: 10.1200/jco.2006.24.18_suppl.4614.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerSkeletal related eventsSRE-free survivalMetastatic androgen-independent prostate cancerDocetaxel-based chemotherapyZoledronic acidDN-101SRE incidenceZA useRisk of SREsDocetaxel-based therapySpinal cord compressionRandomized clinical trialsIndependent prostate cancerAIPC patientsCord compressionProlong survivalProspective studyClinical trialsModern chemotherapyProstate cancerPatientsCochran-MantelChemotherapyEntire groupReduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants
Venner P, Ryan C, Petrylak D, Chatta G, Ruether J, Chi K, Curd J, Beer T. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants. Journal Of Clinical Oncology 2006, 24: 4505-4505. DOI: 10.1200/jco.2006.24.18_suppl.4505.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerSerious adverse eventsThromboembolic eventsDN-101Prostate cancerExact testMetastatic androgen-independent prostate cancerIncidence of TEPlacebo-controlled studyVDR knockout miceEffects of calcitriolFisher's exact testDocetaxel regimenPlacebo groupAdvanced malignanciesAdverse eventsVitamin DBaseline useEfficacy resultsGrade 3Study groupNatural anticoagulantsOral formulationKnockout micePatients
2005
Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC)
Beer T, Ryan C, Venner P, Petrylak D, Chatta G, Ruether J, Henner W, Chi K, Cruickshank S. Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). Journal Of Clinical Oncology 2005, 23: 4516-4516. DOI: 10.1200/jco.2005.23.16_suppl.4516.Peer-Reviewed Original Research